From: [lamon t g] at [u.washington.edu] (Lamont Granquist) Newsgroups: alt.drugs,alt.psychoactives Subject: Interesting LSD/Neuropharm/Psychopathology Articles (improving alt.drugs SNR) Date: 10 May 1994 05:50:12 GMT In a valiant attempt to improve the SNR on alt.drugs... And i'd like to note that all my rants for the past 2 years on the pre-synaptic mechanism of action of LSD on the dorsal and median raphe 5-HT neurons were, apparently, all fucked. =) Apparently this theory was shot down in 1981 by Trulson et al. (Brain Res 215:275-293). The current dogma is that "classic hallucinogens" are 5-HT2 post-synaptic agonists.... Pierce + Peroutka have a mini-review of the mechanism of action of classic hallucinogens in their introduction. I also found "Study of the extraction of LSD from illicit blotters for HPLC determination." J-Forensic-Sci. Sep 1993. 38(5):1105-1110. But it was off at the bindery so i couldn't read the article... Psychopathology Abraham-HD, Aldridge-AM. "Adverse consequences of lysergic acid diethylamide." Addiction. Vol 88:1327-1334. 1993. Overview of acute effects, prolonged psychoses and post-hallucinogen perceptual disorder (PHPD). Biased somewhat towards trying to find problems with LSD and doesn't address the methodological considerations in the studies they cite. Interesting because it clearly states that LSD is not an in vivo clastogen, either weakly or not mutagenic, not teratogenic and not oncogenic (clastogen = breaks chromosomes, mutagen = causes DNA mutations, teratogenic = birth defects, oncogenic = causes cancer) -- and this got by the editors at Addictions. Neuropharmacology Shen-Y, Monsma-FJ, Metcalf-MA, Jose-PA, Hamblin-MW, Sibley-DR, "Molecular Cloning and Expression of a 5-Hydroxytryptamine7 serotonin Receptor Subtype." Journal of Biological Chemistry. Vol 268(24):18200-18204. 25 Aug 1993. Discovery of a 5-HT7 receptor which has a high affinity for LSD (KD = 4.9 +/- 0.78 (n = 5) nM; Bmax = 5-15 pmol/mg protein). Also displays a high affinity for tricyclic antipsychotic and antidepressant agents. It is located primarily in the limbic and cortical regions of the brain. Pierce-PA, Peroutka-SJ. "Antagonist Properties of d-LSD at 5-Hydroxytryptamine2 Receptors." Neuropsychopharmacology. Vol 3(5-6):503-508. 1990. Argues that LSD is a 5-HT2 receptor antagonist and that this tends to rule out the notion that classic hallucinogens work via a 5-HT2 agonist mechanism. Suggests that LSD might be a 5-HT1A or, more likely, 5-HT1C agonist -- although the role of the 5-HT2A receptor subtype is not at present well known. Glennon-RA. "Do Classical Hallucinogens Act As 5-HT2 Agonists or Antagonists?" Neuropsychopharmacology. Vol 3(5-6):509-517. 1990. This is a rebuttal to Pierce and Peroutka's article in the same issue. It argues that LSD is a high-affinity, low-efficacy, nonselective 5-HT agonist, aka a dirty, partial agonist. Thus compared with high-efficacy agonists LSD would exhibit relative antagonist effects. Also, 5-HT1 sites have been shown to behave functionally as 5-HT2 antagonists, particularly 5-HT1A receptors. LSD's non-selective ("dirty") affinity for 5-HT receptors, and in particular 5-HT1A receptors, could explain other evidence which was offered in support of the 5-HT2 antagonist theory, and would explain certain biphasic dose/response curves that LSD has. The author does, however, conclude by noting that the 5-HT1C site may also (or alternatively) play a role in hallucinogenic activity, and that it should be explored. -- Lamont Granquist ([lamon t g] at [u.washington.edu]) "And then the alien anthropologists - Admitted they were still perplexed - But on eliminating every other reason - For our sad demise - They logged the only explanation left - This species has amused itself to death" -- Roger Waters